OncoZenge Appoints Åsa Nilsson as Clinical Research Manager

Stockholm, Sweden – April 9 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Åsa Nilsson as Clinical Research Manager (CRM).

As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is pleased to confirm the appointment of Åsa Nilsson as Clinical Research Manager in support of OncoZenge’s role as sponsor of the project, as well as to lead the company’s efforts in overseeing the trial.

Åsa Nilsson has worked in the pharmaceutical industry for more than 25 years. She started her career as a biomedical scientist and has been working with clinical trials for the last 20 years as Clinical Research Manager. Åsa has experience from leadership- and coordinator roles across several therapeutic areas and indications, and over the past two years she has assisted biotech companies with their sponsor oversight. Notably she has experience from both clinical research organizations (CROs) as well as pharmaceutical companies.
 
“We are thrilled to welcome Åsa to the OncoZenge team”, says Stian Kildal, CEO of OncoZenge. “Åsa brings a wealth of relevant experience that will ensure that OncoZenge can shoulder its responsibility as sponsor of the pivotal phase 3-program towards European approval. That Åsa has prior experience from working with the BupiZenge project is an additional benefit and will ensure we can act decisively and effectively once we have finalized our partner choice for the program”, Stian concludes.
 
 
BupiZenge™ - Potential to be the leading treatment for oral pain.




About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial.

OncoZenge has its headquarters in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.